CRISPR Genome Surgery in Stem Cells and Disease Tissues
Coordonnateur : Tsang Stephen H.
CRISPR Genome Surgery in Stem Cells and Disease Tissues focuses uniquely on the clinical applications of CRISPR/Cas9 based technology. Topics include the latest advances in gene editing and its translational applications to various diseases, including retinal degenerative disease, recessively inherited diseases, and dominantly inherited diseases, to name a few. The book's target audience includes researchers, students, clinicians and the general public. This space that is not currently served by any existing resource, so this publication fills a gap in current literature.
1. History of CRISPR 2. Different Kinds of CRISPR (SpCas9, CjCas9, CaCas9, etc.) 3. Genome engineering in iPSC cells 4. CRISPR manipulations in stem cell lines for neurological diseases 5. Gene editing for the cornea 6. CRISPR screening for eye diseases 7. Employing Non-homologous End Joining and Homology-directed Repair for Treatment of Leber Congenital Amaurosis and Retinal Degeneration 8. Ethics of Gene Editing in Human Stem Cells 9. sGRNA 10. CRISPR vs ZFN/TALEN
Scientists involved in stem cell engineering and gene editing, and individuals of any medical subspecialty
Dr. Tsang graduated from Johns Hopkins University, where he began his medical genetics training under the tutelage of Professor Victor A. McKusick. He received his M.D.-Ph.D. degrees from the NIH-National Institute of General Medical Sciences Medical Scientist Training Program (MSTP) at Columbia University. Dr. Tsang then completed his residency at Jules Stein Eye Institute/UCLA, followed by studies with Professors Alan C. Bird and Graham E. Holder on improving the care of individuals with macular degenerations.
Dr. Tsang is a recognized pioneer in genome surgery in stem cells. Most recently, he has been invited to lecture at the genome surgery workshop during the annual Association for Research in Vision & Ophthalmology (ARVO) 2015, 16 & 18 Annual Meetings; and as a Moderator for Gene Editing/Rewriting the Genome: Moving from Association to Biology and Therapeutics session during the 65th American Society of Human Genetics (ASHG) Annual Meeting, and a lecturer at 2015 & 2016 CRISPR Revolution conferences at Cold Spring Harbor.
In his New York State supported stem cell program (N09G-302), he is examining embryonic stem (ES) cells to model and replace diseased human retinal cells. His contributions were recognized by the 2005 Bernard Becker Association of University Professors in Ophthalmology's Research to Prevent Blindness Award. Dr. Tsang also participates in resident teaching and had been the Columbia ophthalmology basic science course director. He is a member of the American Society of Clinical Investigation.
- Provides a thorough review of CRISPR-Cas9, from discovery to therapy
- Covers the latest advances in gene editing and its translational applications to various diseases
- Written by global leaders in the fields of gene editing and stem cell therapy
Date de parution : 10-2021
Ouvrage de 136 p.
19x23.4 cm
Thème de CRISPR Genome Surgery in Stem Cells and Disease Tissues :
Mots-clés :
?Abortion; Alzheimer’s disease; Base editors; CRISPR; CRISPR-Cas9; CRISPR-tiling; CRISPR/Cas; CRISPR/Cas9; CRISPR/Cas9 efficiency; CRISPR/Cas9 targeting specificity; CRISPRa; CRISPRi; Cas orthologs; Cas12a; Cas13a; Cas9; CjCas9; Clustered regularly interspaced short palindromic repeats; Corneal dystrophy; CrRNA; Critical interfaces; DCas9; Dementia; Dense mutagenesis; Disease modeling; Double-strand break; Drug targets; Endonuclease; Ethics; FnCas9; Functional domains; Gene editing; Genome editing; Genomic engineering; Germline; HDR/NHEJ; High-fidelity SpCas9; Homology-directed repair; Intracameral; Intrastromal; Leber congenital amaurosis; Minimizing CRISPR/Cas9 off-target effects; Mutation dependent; Mutation independent; NCas9; NmCas9; Nonhomologous end joining; Off-targeting; Paired nickases; Personalized medicine; Potentiality argument; Protein complex; RNA-guided RNA-dependent cleavage; Regenerative medicine; Retina; Retinal degeneration; Retinal diseases; Retinal pigment epithelium; SaCas9; SgRNA design; SgRNA optimization; Slippery slope; SpCas9; StCas9; Therapeutics; Topical; TracrRNA; Transcription activator-like effector nucleases (TALENs); Transcription effectors; Zinc-finger nucleases (ZFNs)